Bone Marrow Grafting for Leukemia and Lymphoma
Part of paid clinical trials in Stanford, California.
- Sponsor
- Stanford University
- Study ID
- NCT00186147
- Status
- Enrolling By Invitation
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- collection and storage of tissue samples for research — PROCEDURETissue samples include blood draws for the donor and recipient. A bone marrow sample may be obtained from the recipient. If the recipient undergoes a tissue biopsy for clinical reasons, a small fraction may be removed for research purposes. A small fraction of the donor graft may be removed at the time of collection for research.
Study Details
The purpose of this study is to obtain tissue samples for ongoing studies regarding transplant outcomes and complications.
Key Dates
- Start date
- Mar 31, 1988
- Status verified
- Dec 2025
- Primary completion
- Dec 31, 2069
- Completion
- Dec 31, 2069
Study Design
- Enrollment
- 9,999 participants (estimated)
Arms
- Arm: Graft recipients and donors
Primary Outcome Measure
Identify and characterize proteins and genes that may contribute to the development and progression of cancer. [ Time Frame: blood sample is collected prior transplant, periodically during the first three months and then indefinately at follow up ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Stanford University School of Medicine | Stanford | California | 94305 | - |
Find similar trials in Stanford, CA
By condition
By specialty
By research site
Related Studies
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Pediatric PET/MR Image RegistryRecruiting · Stanford University · Palo Alto, California
- A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsPHASE1/PHASE2 · Recruiting · Turning Point Therapeutics, Inc. · Los Angeles, California
- A Long-term Follow-up Study in Participants Who Received CTX001PHASE3 · Enrolling By Invitation · Vertex Pharmaceuticals Incorporated · Palo Alto, California